Notification of change in major shareholder. New principal shareholder is Asset Value Investors Limited (UK), with voting rights increased to 11.70%. Lohaco? Wait: note: original says \u30ed\u30fc\u30c8\u88fd\u85ac; translated as Rohto Pharmaceutical Co., Ltd. remains as second place. No further outlook described.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4512","jir_company_name":"Wako Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4512-20260828-01.pdf","jir_short_summary":"Notification of change in major shareholder. New principal shareholder is Asset Value Investors Limited (UK), with voting rights increased to 11.70%. Lohaco? Wait: note: original says \u30ed\u30fc\u30c8\u88fd\u85ac; translated as Rohto Pharmaceutical Co., Ltd. remains as second place. No further outlook described.","jir_summary":"### Overview of the Change\nThis press release, based on the submission of the Large-Scale Shareholding Report dated August 27, 2026, confirms a change in our major shareholder, the principal shareholder. The new principal shareholder is Asset Value Investors Limited (London, UK), whose voting rights were 40,560 as of August 20, 2026, representing 11.70% of total voting rights, ranking it first.\n\n### Outlook and Impact\nThis matter is based on the submission of the Large-Scale Shareholding Report, and no specific outlook is stated. With Rohto Pharmaceutical Co., Ltd. no longer a major shareholder, the shareholder ranking shifted to 2nd place, but the specific impact on business strategy or capital policy remains unknown at this time.","jir_financial_highlights":"Voting rights of the new principal shareholder: 40,560 units (Previous: +3,629 units\uff0811.70\uff05\uff09)\nNumber of shares owned by the new principal shareholder: 4,056,000 shares (+0 shares\uff08after-change value\uff09)\nVoting rights of Rohto Pharmaceutical: 39,719 units (Previous: 0)","jir_category":"","jir_hashtags":"#ChangeInShareholderStructure","jir_key_figures":"Voting rights of the new principal shareholder: 40,560 shares\nNumber of shares owned by the new principal shareholder: 4,056,000 shares\nVoting rights of Rohto Pharmaceutical: 39,719 shares","jir_meta_title":"Wako Pharmaceutical \u2013 Notice of Change in Major Shareholder | August 2026","jir_meta_description":"Wako Pharmaceutical's major shareholder has shifted to Asset Value Investors Limited. Key points include the new principal shareholder's voting rights and percentage, and the change in the ranking of the former principal shareholder. Impact going forward is to be determined.","jir_og_title":"Wako Pharmaceutical \u2013 Notice of Change in Major Shareholder | August 2026","jir_og_description":"Notice of major shareholder change. New principal shareholder is Asset Value Investors Limited, voting rights 11.70%, impact TBD.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58985,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-107842","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n